Lynch Syndrome: Genes, Cancer Risk and Inheritance

01 / 16

What is Lynch syndrome?

Lynch syndrome is the most common form of hereditary colorectal cancer. A person inherits one working and one faulty copy of a DNA mismatch-repair gene; if the working copy is later lost in a cell, copying errors can accumulate and allow cancer to develop. ^[1,2,5]

The mismatch-repair system acts like proofreading for DNA. MLH1, MSH2, MSH6 and PMS2 proteins identify and repair errors made as cells copy their DNA; EPCAM deletions can indirectly switch off MSH2. GeneReviews now defines Lynch syndrome by a confirmed pathogenic germline variant, making it narrower than HNPCC, the older name for Lynch syndrome. “Muir–Torre syndrome” is also a historical term within the Lynch spectrum. ^[1]

02 / 16

Which genes cause Lynch syndrome?

Lynch syndrome is caused by a pathogenic variant in MLH1, MSH2, MSH6 or PMS2, or by a deletion at the end of EPCAM that switches off neighbouring MSH2. MLH1 and MSH2 generally carry the highest colorectal risk; MSH6 and PMS2 are lower. ^[1]

The five Lynch syndrome genes, their roles and typical cancer patterns.
Gene	What it does	Pattern to know
MLH1	Core mismatch-repair partner	High colorectal and endometrial risk
MSH2	Recognises DNA-copying errors	High colorectal risk; strongest urinary-tract and prostate signal
MSH6	Works with MSH2	Endometrial risk similar to MLH1; lower colorectal risk
PMS2	Works with MLH1	Lowest estimated risks of the four repair genes
EPCAM	Not itself a repair gene; a 3′ deletion silences MSH2	Acts through MSH2; prospective gene-specific data remain limited

“Most common gene” has two valid answers. Clinic-based family series are dominated by MLH1 and MSH2; one Illinois series reported 32% MLH1 and 38% MSH2. Population studies find MSH6 and PMS2 variants more prevalent because they can be less penetrant and therefore less likely to reach hereditary-cancer clinics. ^[1,12]

Pathogenic and likely pathogenic variants are managed alike. A variant of uncertain significance neither confirms nor rules out Lynch syndrome. ^[1]

03 / 16

How is Lynch syndrome inherited?

Lynch syndrome is inherited in an autosomal dominant pattern: a parent with a Lynch variant has a 50% chance of passing it to each child, whether the child is a son or daughter and whether the carrier is the mother or father. ^[2,5]

50%

Each pregnancy is an independent event. A new, or de novo, variant can arise without a family history, but most carriers inherited the variant. The gene does not skip generations; incomplete penetrance and small families can make it appear to. Testing relatives for a known family variant is called cascade testing. ^[1,5]

04 / 16

How common is Lynch syndrome?

GeneReviews estimates that Lynch syndrome affects between 1 in 280 and 1 in 600 people and accounts for about 3% of colorectal cancers in unselected patients. The CDC estimates roughly 3,800 colorectal and 1,600 uterine cancers each year in the United States are attributable to it. ^[1,2]

Estimate	Source	Context
1 in 280–600	GeneReviews ^[1]	Range across populations and methods
About 1 in 279	MedlinePlus / Cleveland Clinic ^[13,14]	Frequently cited US estimate
About 1 in 300	Patient education estimates	Rounded communication figure

The numbers differ because studies sample different populations, genes and ascertainment methods. The CDC estimates Lynch syndrome contributes 2–5% of colorectal cancers and about 3% of endometrial cancers. ^[2]

05 / 16

Which cancers does Lynch syndrome cause, and how high is the risk?

Lynch syndrome raises colorectal and endometrial cancer risk most, and also ovarian, stomach, small-bowel, urinary-tract, bile-duct, pancreatic, prostate, brain and sebaceous skin cancer risk. By age 65, colon cancer risk is about 36% in women and 48% in men with MLH1, versus 3% and 9.5% with PMS2. ^[1,2]

Gene-specific cumulative cancer risk through age 65 from GeneReviews Table 3 and the Prospective Lynch Syndrome Database.
Cancer	General population	MLH1	MSH2	MSH6	PMS2
Colon, women / men	0.45% / 0.6%	36% / 48%	30% / 41.5%	10% / 13%	3% / 9.5%
Rectum, women / men	0.3% / 0.5%	5% / 6%	8% / 13%	4% / 5%	2% / 0%
Endometrium	0.6%	32%	38%	32%	13%
Ovary	0.5%	8%	11%	3%	2.5%
Ureter / kidney, women / men	0.2% / 0.35%	2% / 2.5%	10% / 11.5%	3% / 1%	0% / 0%
Prostate, men	1%	5%	11%	3%	3%

Cumulative risk by age 65; general-population figures are through age 64. Source: GeneReviews Table 3, drawing on the 2023 Prospective Lynch Syndrome Database update. These are cohort estimates, not individual predictions. ^[1]

A separate PLSD analysis through age 75 estimated colorectal risk at 48.3% in women and 57.1% in men with MLH1; 46.6% and 51.4% with MSH2; 20.3% and 18.2% with MSH6; and 10.4% combined with PMS2. Endometrial risk was 37.0%, 48.9% and 41.1% for MLH1, MSH2 and MSH6; ovarian risk was 11.0%, 17.4% and 10.8%. Different cohorts and age cut-offs explain why these values differ from the table. ^[3]

Older, clinic-based series produced the familiar “up to 80%” figure. Prospective evidence supports lower, gene-specific estimates. Median colorectal cancer onset is 47–56 for MLH1/MSH2, 55–60 for MSH6 and 66–71 for PMS2. Current evidence does not establish breast cancer as part of the Lynch spectrum; a family history dominated by breast or ovarian cancer may warrant reading about BRCA1 and BRCA2. ^[1,5]

06 / 16

Can you have Lynch syndrome and never get cancer?

Yes. Lynch syndrome has incomplete penetrance, meaning some people with a pathogenic variant never develop cancer. By age 65, about 48% of men with MLH1 develop colon cancer, so roughly half have not; risk varies substantially by gene, sex and age. ^[1]

A carrier is neither certain to develop cancer nor “safe” because relatives did not. The practical value of knowing is access to risk-appropriate surveillance intended to prevent colorectal cancer or find cancers earlier.

07 / 16

Does Lynch syndrome cause symptoms?

Lynch syndrome itself usually causes no symptoms. Symptoms appear only if a cancer develops—such as blood in stool, a persistent change in bowel habits, abnormal vaginal bleeding, abdominal pain, unexplained weight loss or blood in urine—so many carriers first learn through a relative’s diagnosis. ^[5]

Reasons to ask about genetic counselling include colorectal or endometrial cancer before 50, more than one Lynch-related cancer in one person, or several relatives on the same side of the family with related cancers. A whole-genome report does not detect an existing cancer.

08 / 16

Lynch syndrome in men

Men with Lynch syndrome generally have a higher colorectal cancer risk than women with the same gene: by age 65, MLH1-associated colon cancer risk is 48% in men versus 36% in women; for MSH6 it is 13% versus 10%. ^[1]

Men also face prostate, bladder and upper urinary-tract risks, most clearly with MSH2. Surveillance is centred on colonoscopy, with additional assessment depending on gene, family history and evolving guidance. This overview does not prescribe a schedule.

09 / 16

Prostate cancer and Lynch syndrome

Prostate cancer is part of the Lynch syndrome cancer spectrum, mainly with MSH2 variants. PLSD estimated cumulative incidence by age 75 at 23.8% for MSH2 and 13.8% for MLH1 carriers. Expert guidance on routine PSA screening differs, so carriers should discuss it with a clinician. ^[3]

By age 65

11% · MSH2

Versus 5% MLH1 and 3% MSH6/PMS2. ^[1]

Meta-analysis

2.13×

Relative risk in clinic-based cohorts; molecular studies estimated 3.67×. ^[7]

IMPACT first round

4.3% · MSH2

Cancer detected in MSH2 carriers versus 0.3% of non-carrier controls. ^[6]

A study of 188 men reported a standardised rate ratio of 4.87, while estimates across studies vary by design. IMPACT used a PSA threshold of 3.0 ng/mL and found cancer in 4.3% of MSH2 and 3.0% of MSH6 carriers in its first screening round. These findings do not establish one screening schedule; current recommendations require clinician interpretation. Tumour mismatch-repair testing after a prostate cancer diagnosis is a separate clinical question. ^[6,8,18]

10 / 16

How do you find out if you have Lynch syndrome?

Lynch syndrome is confirmed by finding a pathogenic germline variant through clinical testing of blood or saliva, usually with a multigene panel that includes EPCAM deletion analysis. Tumour testing for microsatellite instability (MSI) or missing mismatch-repair proteins (IHC) is a separate screen that identifies who needs germline testing. ^[1,4]

NCCN Version 1.2026 recommends mismatch-repair testing for all colorectal and endometrial cancers. Germline testing asks what was inherited and can be passed on; tumour testing asks what is happening in the cancer. Testing is generally considered after colorectal or endometrial cancer, a qualifying family history, or when a relative has a known variant. ^[4]

Whole-genome sequencing is far broader and more comprehensive in genomic scope than a small Lynch-focused panel: it reads across the genome and can support reporting in health categories beyond hereditary cancer. Here, “more comprehensive” means broader genome and report-category coverage—not that WGS is automatically a better clinical diagnostic test for Lynch syndrome.

A decision-oriented comparison of a small Lynch-focused hereditary-cancer gene panel and whole-genome sequencing.
Decision point	Small Lynch-focused panel	Whole-genome sequencing
Scope	A deliberately limited set of hereditary-cancer genes selected to answer a specific clinical question	DNA sequence across the genome, with potential reporting across multiple health categories
Best use	Often the first clinical route for a strong family history or a known familial variant	Broad genomic exploration beyond one syndrome; not automatically the better Lynch diagnostic test
Variant methods	Can include EPCAM deletion analysis and specialised methods selected for Lynch-associated variant types	Do not assume every Lynch gene or relevant variant class is covered or reported; HLI’s scope here remains unconfirmed
Beyond Lynch	Intentionally narrow, with limited findings outside the ordered panel	Far broader genomic scope and more report categories than a small targeted panel
Next steps	Interpret with the ordering clinician or genetic counsellor	Clinically confirm relevant findings; a normal report does not rule out Lynch syndrome

WGS does not replace tumour testing, genetic counselling or confirmatory testing, and it does not detect an existing cancer. If Lynch syndrome is the specific concern, discuss the most appropriate clinical route with a clinician or genetic counsellor.

See what the $599 HLI whole-genome service includes

What is the 3/2:1 rule for Lynch syndrome?

The “3-2-1 rule” summarises the Amsterdam criteria: at least three relatives with a Lynch-related cancer, one a first-degree relative of the other two, spanning at least two generations, with one diagnosis before 50. Amsterdam II is highly specific but only about 30% sensitive, so not meeting it does not rule out Lynch syndrome. ^[10]

11 / 16

How is Lynch syndrome managed?

Managing Lynch syndrome means surveillance and prevention rather than treating the syndrome itself. GeneReviews lists colonoscopy every 1–2 years from age 20–25 for MLH1, MSH2 and EPCAM, and every 1–3 years from age 30–35 for MSH6 and PMS2, with other checks tailored to gene and history. ^[1]

Intervals differ among expert sources, and every age and interval needs individual review. Decisions about aspirin, surgery, organ-specific surveillance or cancer treatment belong with a hereditary-cancer team; this page does not provide treatment advice.

12 / 16

What is the outlook for someone with Lynch syndrome?

Outcomes after the cancers most common in Lynch syndrome can be good when disease is found early. In the Prospective Lynch Syndrome Database, ten-year survival after the most common Lynch-associated cancers exceeded 80%, but outcomes still depend on cancer type, gene, sex and stage. ^[3,15]

This evidence does not promise normal life expectancy for every carrier. It supports structured surveillance and timely care rather than predicting one person’s future.

13 / 16

Lynch syndrome, insurance and privacy

In the United States, GINA bars health insurers from using genetic information for coverage or premium decisions and bars most employers from using it in hiring or firing. It does not cover life, disability or long-term-care insurance, although some states add protections. ^[9]

The employment rule generally does not cover employers with fewer than 15 employees or the US military. Rules can change and this is not legal advice. Human Longevity’s handling of personal information is described in its Privacy Policy.

14 / 16

Lynch syndrome FAQ

Q1Is Lynch syndrome inherited from your mother or your father?

Lynch syndrome can be inherited from either parent. A carrier has a 50% chance of passing the familial variant to each child, regardless of the parent’s or child’s sex. ^[2]

Q2What age does Lynch syndrome cancer usually start?

Median colorectal cancer onset is about 47–56 for MLH1 and MSH2, 55–60 for MSH6, and 66–71 for PMS2 carriers. These are group medians, not a forecast for one person. ^[1]

Q3Is Lynch syndrome a big deal?

Lynch syndrome is the most common cause of hereditary colorectal cancer and raises several cancer risks, but severity differs by gene. Surveillance and earlier detection can materially change outcomes. ^[1,2]

Q4Does Lynch syndrome skip generations?

The variant itself does not skip generations. Reduced penetrance, small families, early deaths, or inheritance through relatives who never develop cancer can make the pattern look as though it did. ^[1]

Q5Can stomach cancer risk come through the father’s side?

Yes. A Lynch syndrome variant can come from either parent. By age 65, estimated stomach cancer risk is 2–3% for MLH1 and 3–4% for MSH2 carriers, depending on sex. ^[1]

Q6What is the ICD-10 code for Lynch syndrome?

ICD-10-CM commonly uses Z15.09, “genetic susceptibility to other malignant neoplasm.” Coding can depend on the encounter and diagnosis, so a clinician or coding professional should confirm the current code. ^[16]

Q7What is the difference between Lynch syndrome and HNPCC?

HNPCC is the older, family-history-based term. Lynch syndrome now usually means a confirmed pathogenic variant affecting DNA mismatch repair, so the modern term is more specific. ^[1]

Q8How is Lynch syndrome different from FAP?

Lynch syndrome is caused by mismatch-repair failure and usually does not cause hundreds of polyps. Familial adenomatous polyposis is a different inherited syndrome, usually involving APC and extensive colorectal polyposis. ^[1]

15 / 16

Where a whole-genome report fits

A whole-genome sequence reads DNA across the genome and can support broad inherited-health analysis, but it is not the same as a clinical Lynch syndrome test. HLI has not confirmed that its report covers all five Lynch genes or the specialised variant types that matter here.

The safe interpretation

A genome finding is a starting point—not a diagnosis.

If a report ever lists a variant in a Lynch-associated gene, the clinical path is a genetic counsellor and confirmatory testing. WGS is not tumour testing, does not detect an existing cancer, and does not replace family-history-based care. A normal report does not rule out Lynch syndrome.

16 / 16

How whole-genome sequencing compares with the other ways to learn your Lynch status

A whole-genome sequence is broader than a Lynch syndrome panel but is not a better first step for most people with a strong family history. A clinician-ordered panel is built for this question and includes EPCAM deletion analysis. HLI’s $599 service adds breadth across cardiovascular, pharmacogenomic and other categories; it does not replace genetic counselling or tumour testing. ^[1]

How targeted tests, clinical panels, tumour testing, 23andMe and whole-genome sequencing differ.
Route	What it is	Where it wins	Where WGS differs
Known family variant	One targeted test for the exact variant a relative carries	Most direct and definitive when the family variant is known	WGS is not needed; use the targeted test first
Clinical hereditary-cancer panel	MLH1, MSH2, MSH6, PMS2, EPCAM 3′ deletion analysis and other genes	Built for this question and often the right first test for a qualifying history	A WGS report does not replace counselling or clinically ordered testing
Tumour-first pathway	MSI, IHC and sometimes MLH1 methylation analysis in a colorectal or endometrial tumour	The route for someone who already has one of these cancers	WGS does no tumour testing and does not detect existing cancer
23andMe	Standard reports do not include Lynch syndrome; a higher-tier clinician-ordered exome report lists MLH1, MSH2, MSH6 and PMS2, not EPCAM	Consumer-accessible route to a clinician-ordered report for those four genes	Different technology and scope; neither route should be assumed complete
HLI $599 whole-genome service	Approximately 30× average coverage, saliva kit, CLIA lab and a physician-ready report; confirmed cancer scope includes BRCA1/2 among other genes	Breadth across report categories and potential future reinterpretation	Lynch-gene scope and handling of difficult variant classes are unconfirmed; 30× is an average, not a guarantee at each position

Important Lynch-associated findings can require dedicated laboratory methods. PMS2 has homologous pseudogenes that complicate sequencing and interpretation; EPCAM 3′ deletions require deletion analysis, and MLH1 epimutations require methylation analysis. HLI has not confirmed how its report handles these features. ^[1]

In 2025, researchers reported whole-genome sequencing finding a deep intronic MLH1 variant missed by a panel within a tumour-guided clinical workflow. That case shows what genomes can add in specialist hands; it is not evidence about a consumer report. ^[17]

See what the $599 genome service includes

Sources and review notes

Sources were reviewed October 5, 2026. GeneReviews and guideline versions should be checked at least every six months and whenever the source is revised. Prostate-screening wording and all surveillance ages require clinical reviewer sign-off before publication.